These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 9779381)

  • 21. Localization of a determinant mediating partial macrolide resistance in Staphylococcus aureus.
    Matsuoka M; Endou K; Nakajima Y
    Microbiol Immunol; 1990; 34(8):643-52. PubMed ID: 2126334
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evolution and epidemiology of MLS resistance.
    Duval J
    J Antimicrob Chemother; 1985 Jul; 16 Suppl A():137-49. PubMed ID: 3932300
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anhydrolide macrolides. 1. Synthesis and antibacterial activity of 2,3-anhydro-6-O-methyl 11,12-carbamate erythromycin A analogues.
    Elliott RL; Pireh D; Griesgraber G; Nilius AM; Ewing PJ; Bui MH; Raney PM; Flamm RK; Kim K; Henry RF; Chu DT; Plattner JJ; Or YS
    J Med Chem; 1998 May; 41(10):1651-9. PubMed ID: 9572890
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of beta-lactam agents in the treatment of community-acquired pneumonia.
    Garau J
    Eur J Clin Microbiol Infect Dis; 2005 Feb; 24(2):83-99. PubMed ID: 15696306
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Short-course beta-lactam treatment for community-acquired pneumonia.
    Stralin K; Sjöberg L; Holmberg H
    Clin Infect Dis; 2004 Mar; 38(5):766-7. PubMed ID: 14986269
    [No Abstract]   [Full Text] [Related]  

  • 26. The hospitalist perspective on treatment of community-acquired bacterial pneumonia.
    Amin AN; Cerceo EA; Deitelzweig SB; Pile JC; Rosenberg DJ; Sherman BM
    Postgrad Med; 2014 Mar; 126(2):18-29. PubMed ID: 24685965
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A dyadic plasmid that shows MLS and PMS resistance in Staphylococcus aureus.
    Matsuoka M; Endou K; Kobayashi H; Inoue M; Nakajima Y
    FEMS Microbiol Lett; 1997 Mar; 148(1):91-6. PubMed ID: 9066116
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Empirical therapy of community-acquired pneumonia: macrolides are not ideal choices.
    Bartlett JG
    Semin Respir Infect; 1997 Dec; 12(4):329-33. PubMed ID: 9436960
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Beta-lactamase producers and other bacteria: which ones to take into consideration and when? The viewpoint of the pneumologist].
    Poirier R
    Presse Med; 1998 Sep; 27 Suppl 4():14-5. PubMed ID: 9798478
    [No Abstract]   [Full Text] [Related]  

  • 30. Epidemiologic trends in nosocomial and community-acquired infections due to antibiotic-resistant gram-positive bacteria: the role of streptogramins and other newer compounds.
    Jones RN; Low DE; Pfaller MA
    Diagn Microbiol Infect Dis; 1999 Feb; 33(2):101-12. PubMed ID: 10091033
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Staphylococcus aureus plasmid that specifies constitutive macrolide-lincosamide-streptogramin B resistance contains a novel deletion in the ermC attenuator.
    Catchpole I; Dyke KG
    FEMS Microbiol Lett; 1990 May; 57(1-2):43-7. PubMed ID: 2116351
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Empirical treatment of influenza-associated pneumonia in primary care: a descriptive study of the antimicrobial susceptibility of lower respiratory tract bacteria (England, Wales and Northern Ireland, January 2007-March 2010).
    Blackburn RM; Henderson KL; Lillie M; Sheridan E; George RC; Deas AH; Johnson AP
    Thorax; 2011 May; 66(5):389-95. PubMed ID: 21357586
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phenotypes of staphylococcal resistance to macrolides, lincosamides and streptogramin B (MLS) in a Turkish university hospital.
    Tunçkanat F; Arikan S
    Zentralbl Bakteriol; 2000 Jan; 289(8):827-33. PubMed ID: 10705614
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Comparative antimicrobial activity of RP 59,500 (quinupristin-dalfopristin), the first semisynthetic injectable streptgramin, against gram-positive cocci and other recent clinical pathogens].
    Nakashio S; Iwasawa H; Iino S; Shimada J
    Jpn J Antibiot; 1997 Oct; 50(10):844-53. PubMed ID: 9412874
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quinupristin-dalfopristin resistance in Streptococcus pneumoniae: novel L22 ribosomal protein mutation in two clinical isolates from the SENTRY antimicrobial surveillance program.
    Jones RN; Farrell DJ; Morrissey I
    Antimicrob Agents Chemother; 2003 Aug; 47(8):2696-8. PubMed ID: 12878545
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gram-positive resistance: challenge for the development of new antibiotics.
    Baquero F
    J Antimicrob Chemother; 1997 May; 39 Suppl A():1-6. PubMed ID: 9511055
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Various prospective approaches to the treatment of nonspecific lung diseases].
    Sil'vestrov VP; Vanina NF
    Ter Arkh; 1980; 52(3):3-12. PubMed ID: 6966837
    [No Abstract]   [Full Text] [Related]  

  • 38. Characterization of plasmids that confer inducible resistance to 14-membered macrolides and streptogramin type B antibiotics in Staphylococcus aureus.
    Jánosi L; Nakajima Y; Hashimoto H
    Microbiol Immunol; 1990; 34(9):723-35. PubMed ID: 2126591
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activity of nine oral agents against gram-positive and gram-negative bacteria encountered in community-acquired infections: use of pharmacokinetic/pharmacodynamic breakpoints in the comparative assessment of beta-lactam and macrolide antimicrobial agents.
    Peric M; Browne FA; Jacobs MR; Appelbaum PC
    Clin Ther; 2003 Jan; 25(1):169-77. PubMed ID: 12637118
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Microbiological profile of telithromycin, the first ketolide antimicrobial.
    Felmingham D
    Clin Microbiol Infect; 2001; 7 Suppl 3():2-10. PubMed ID: 11523558
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.